Devising a best practice approach to prophylaxis in boys with severe haemophilia: Evaluation of current treatment strategies

Haemophilia

Volumn 16, Issue SUPPL. 2, 2010, Pages 4-9

  Carcao, M ^a   Chambost, H ^b   Ljung, R ^c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b TIMONE HOSPITAL   (France)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Haemophilia; Prophylaxis; Protocol; Replacement factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ARTHROPATHY; BRAIN HEMORRHAGE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; TREATMENT INDICATION; VASCULAR ACCESS DEVICE;

ADOLESCENT; AGE FACTORS; BLOOD COAGULATION FACTORS; CANADA; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FRANCE; HEMARTHROSIS; HEMOPHILIA A; HUMANS; INFANT; MALE; PATIENT COMPLIANCE; SWEDEN;

EID: 76749136824     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02196.x     Document Type: Review

References (31)

1. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost 2009, 101:674-81.
2. Chambost H, Ljung R. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia 2005, 11:92-9.
3. Berntorp E, Boulyjenkov V, Brettler D. Modern treatment of haemophilia. Bull World Health Organ 1995, 73:691-701.
4. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996, 92:973-8.
5. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 1996, 129:424-31.
6. Manco-Johnson MJ, Abshire TC, Shapiro AD. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-44.
7. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992, 232:25-32.
8. Van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol 1971, 45:120-7.
9. Butler RB, McClure W, Wulff K. Practice patterns in haemophilia A therapy - a survey of treatment centres in the United States. Haemophilia 2003, 9:549-54.
10. Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003, 9(Suppl 1):19-26.
11. Biss TT, Chan AK, Blanchette VS. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008, 14:923-30.
12. Ota S, Mclimont M, Carcao MD. Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study. Haemophilia 2007, 13:12-20.
13. Donadel-Claeyssens S. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006, 12:124-7.
14. Berntorp E, Astermark J, Björkman S. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003, 9(Suppl 1):1-4.
15. Feldman BM, Pai M, Rivard GE. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006, 4:1228-36.
16. Meunier S, Trossaërt M, Berger C. French Guidelines. Long term prophylaxis for severe haemophilia A and B children to prevent haemophiliac arthropathy. Arch Ped 2009, 16:1571-8.
17. Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 2007, 13(Suppl 2):16-22.
18. van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005, 11:438-43.
19. Barnes C, Rivard GE, Poon MC. Canadian multi-institutional survey of immune tolerance therapy (ITT) - experience with the use of recombinant factor VIII for ITT. Haemophilia 2006, 12:1-6.
20. Ewenstein BM, Valentino LA, Journeycake JM. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004, 10:629-48.
21. Carcao MD. Side-effects and venous access issues with immune tolerance therapy. Haemophilia 2009, 15:494-500.
22. Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol 2007, 138:580-6.
23. Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol 2008, 140:378-84.
24. Stieltjes N, Calvez T, Demiguel V. Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death. Haemophilia 2005, 11:452-8.
25. Berntorp E, Shapiro A, Astermark J. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006, 12(Suppl 6):1-7.
26. Santagostino E, Mancuso ME, Rocino A. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005, 130:422-7.
27. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007, 109:4648-54.
28. Lorenzo JI, López A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001, 113:600-3.
29. van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003, 89:475-9.
30. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007, 5:1383-90.
31. Sharathkumar A, Lillicrap D, Blanchette VS. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003, 1:1228-36.